Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | GRM6 | O15303 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19256438 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL19388955 | 0.78 | APLNR (0.40) | GRM2GRM3CYP1A2ALOX15SLC1A2 | |
| SCHEMBL2173741 | 0.75 | SLC1A2 (0.33) | SLC1A2MEN1KMT2A | |
| Acetic Acid SCHEMBL28036317 | 0.72 | ALPL (0.34) | — | |
| SCHEMBL40623 | 0.71 | CYP1A2 (0.53) | GRM2GRM3CYP1A2ALOX15SLC1A2 | |
| SCHEMBL3145095 | 0.71 | CYP1A2 (0.53) | GRM2GRM3CYP1A2ALOX15SLC1A2 | |
| SCHEMBL40622 | 0.71 | CYP1A2 (0.53) | GRM2GRM3CYP1A2ALOX15SLC1A2 | |
| Chloromethane SCHEMBL22092026 | 0.71 | CYP1A2 (0.48) | GRM2GRM3CYP1A2ALOX15SLC1A2 | |
| SCHEMBL19256482 | 0.70 | ALPL (0.30) | — | |
| Hydrochloric Acid SCHEMBL1269592 | 0.69 | CYP1A2 (0.52) | GRM2GRM3CYP1A2ALOX15SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2022-12-01 | — | — | US | disclosed |
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2021-01-19 | — | — | US | disclosed |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | EOLAS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3414241-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139603-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | GRM2 221/4885GRM3 209/4885CYP1A2 2948/4885 |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | GRM2 221/4885GRM3 209/4885CYP1A2 2948/4885 |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | GRM2 221/4885GRM3 209/4885CYP1A2 2948/4885 |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | GRM2 221/4885GRM3 209/4885CYP1A2 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.